Kairos Pharma, LTD. (KAPA): Form 8-K filed 2026-11-03
- Accepted by EDGAR
- 2026-11-03 11:50 ET
- Event date
- 2026-10-29
- Accession no.
- 0001493152-26-049744
- Original filing
- SEC EDGAR filing index
Items reported
- Item 1.01: Entry into a Material Definitive Agreement
The company signed a material agreement outside the ordinary course of business, or materially amended one. Typical examples are credit agreements, merger agreements, large supply or licensing contracts and financing arrangements. - Item 8.01: Other Events
A voluntary disclosure of an event the company considers important to security holders that no other Item covers, such as a dividend declaration, a buyback program, litigation updates or product news. - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | form8-k.htm |
| EX-10.2 | EX-10.2 | ex10-2.htm |
| EX-10.3 | EX-10.3 | ex10-3.htm |
| EX-10.4 | EX-10.4 | ex10-4.htm |
| EX-99.1 | EX-99.1 | ex99-1.htm |
| EX-99.2 | EX-99.2 | ex99-2.htm |
This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.